Wealth Enhancement Advisory Services
ACAD icon

Wealth Enhancement Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$622K Buy
31,775
+777
+3% +$20.9K ﹤0.01% 2601
2026
Q2 		$813K Buy
30,998
+830
+3% +$18.3K ﹤0.01% 2240
2026
Q1 		$670K Buy
30,168
+1,947
+7% +$46.5K ﹤0.01% 2103
2025
Q4 		$760K Sell
28,221
-1,506
-5% -$36K ﹤0.01% 2146
2025
Q3 		$640K Buy
29,727
+5,352
+22% +$127K ﹤0.01% 2166
2025
Q2 		$511K Buy
+24,375
New +$453K ﹤0.01% 2210

Other funds holding ACAD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Wealth Enhancement Advisory Services's ACAD Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Acadia Pharmaceuticals (ACAD) stake by 2.5% in Q3 2026, buying an estimated $20.9K and bringing the position to 31,775 shares worth $622K. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Wealth Enhancement Advisory Services first reported a position in ACAD in Q2 2025 and has held it in 6 quarters since. The position peaked at $813K in Q2 2026. 263 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Wealth Enhancement Advisory Services held 31,775 shares of Acadia Pharmaceuticals worth $622K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 777 Acadia Pharmaceuticals shares in Q3 2026, an estimated $20.9K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2601 holding.
  • Wealth Enhancement Advisory Services first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Acadia Pharmaceuticals position peaked at $813K in Q2 2026.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.